Literature DB >> 17182378

[Epithelial advanced ovarian carcinoma in the central region of Tunisia: therapeutic results and prognostic factors on 104 patients].

Leila Ben Fatma1, Makram Hochlef, Olfa Gharbi, Amel Landolsi, Sami Limam, Imene Chabchoub, Nadra Cherif, Sassi Bouguizene, Tahar Yacoubi, Mohamed Bibi, Hedi Khairi, Slim Ben Ahmed.   

Abstract

Between 1994 and 2004, 104 patients with epithelial advanced ovarian cancer were treated in the central region of Tunisia (81 stage III and 23 stage IV). Average age of patients was 54 years. Primary surgery was optimal (residue < 2 cm) in 40 cases (38,5 % of patients). Fifty nine patients were treated with neo adjuvant chemotherapy based on platinum, associated to paclitaxel in 19 % of cases. Interval debulking surgery interested 30 patients and was optimal in 66,7 % of cases. Global survive was 57 % at 2 years and 27 % at 5 years. Survival rate for patients treated with optimal debulking surgery was similar to that of those treated with initial optimal surgery. Prognostic factors for a better survive were : age < 40 years (p < 0,05), stage III (p < 0,01), a normal level of CA125 after surgery (p < 0,01), primary optimal initial surgery (p < 0,02) and response to neoadjuvant chemotherapy (p < 0,01). Prognosis of ovarian carcinoma is worse in Tunisia as like as in the world. In case of extensive tumor, the neoadjuvant chemotherapy before interval debulking surgery permits to improve survive and quality of life in some patients.

Entities:  

Mesh:

Year:  2006        PMID: 17182378

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  3 in total

1.  Overexpression of Annexin A1 Is an Independent Predictor of Longer Overall Survival in Epithelial Ovarian Cancer.

Authors:  Raoudha Doghri; Pascal Finetti; Karima Mrad; Maroua Manai; Rihab Bouabsa; Mohamed Manai; Daniel Birnbaum; François Bertucci; Lamia Charfi; Maha Driss
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

2.  [A retrospective study of ovarian cancer with a median follow of 42 months].

Authors:  Fanomezantsoa Raherinantenaina; Solonirina Davidà Rakotomena; Nomeharisoa Rodrigue Emile Hasiniatsy; Felantsoa Auberlin Rakototiana; Florine Rafaramino; Hery Nirina Rakoto Ratsimba
Journal:  Pan Afr Med J       Date:  2015-03-09

3.  Stromal Expression of MARCKS Protein in Ovarian Carcinomas Has Unfavorable Prognostic Value.

Authors:  Raoudha Doghri; Maroua Manai; Pascal Finetti; Maha Driss; Emilie Agavnian; Marc Lopez; Meriam Elghardallou; Emmanuelle Charafe-Jauffret; Mohamed Manai; Max Chaffanet; Daniel Birnbaum; Karima Mrad; François Bertucci
Journal:  Int J Mol Sci       Date:  2017-12-23       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.